|
 |
|
|
|||
 |
 
  
|
 |
|
Feb. 11, 2013 Source: Sanofi news release To view complete report, click here. Commenting on the Group's performance in 2012, Sanofi Chief Executive Officer, Christopher A. Viehbacher said, "2012 was a turning point for Sanofi with the loss of exclusivity in the U.S. for several significant legacy drugs. Despite the effect of the patent cliff, Sanofi was able to grow sales and mitigate the impact on Business EPS1. At the same time, Sanofi was able to obtain nine significant regulatory approvals and submit six new files with regulatory agencies. Although the financial results in the first half will experience a residual effect from patent expirations, we expect to resume growth in the second half of 2013. This will be driven primarily by continued strong performance from our growth platforms2 which now represent more than 70% of our sales and rose nearly 10%3 in 2012. We are on track to meet our 2012-2015 objectives for sustainable growth". Animal Health Sales of Merial grew 6.6% to €506 million in the fourth quarter, driven by Emerging Markets (+17.6% to €172 million). Full-year sales of Merial totaled €2,179 million, an increase of 3.1%. Sales in Emerging Markets reached €579 million in 2012, an increase of 14.0%. Fourth-quarter sales of the Companion Animals segment reached €260 million, an increase of 2.6%, mainly driven by Heartgard® in the U.S. (which benefited from a competitor supply issue), vaccines and the new combination parasiticide, Frontline® TRITAK, which was launched in the U.S. at the beginning of September. Sales of the Frontline®/fipronil family of products were €129 million down 3.0% in the fourth quarter. Full-year sales of the companion animals segment were €1,372 million, up 1.8%. In 2012, sales of the Frontline® umbrella brand remained the only blockbuster in Animal Health with sales of $1 billion (€775 million). Sales of the Production Animals segment were €246 million in the fourth quarter, up 10.8%, driven by the avian segment (+17.9%) and the swine segment (+30.5%) which includes the acquisition of Newport Laboratories in the U.S. completed in March 2012. The ruminant segment also recorded a solid performance over the quarter with 10% growth. Full-year 2012 sales of the Production Animals segment totaled €807 million, an increase of 5.1%. In December 2012, Sanofi entered into a binding agreement to acquire the animal health division of the Indian company Dosch Pharmaceuticals Private Limited, creating a market entry for Merial in that country's strategically important and growing animal health sector. The agreement is subject to regulatory approval and is expected to close in the first half of 2013. Tweet |
|
|
|
|
|
|
|
|
 |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
